keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical BCG

keyword
https://www.readbyqxmd.com/read/29322799/predictors-and-prognostic-implications-of-clinical-decisions-in-patients-with-primary-high-risk-non-muscle-invasive-bladder-cancer-results-of-a-cross-country-retrospective-study
#1
S Poletajew, R Biernacki, P Buraczynski, J Chojnacki, S Czarniecki, D Gajewska, T Pohaba, J Sondka-Migdalska, M Skrzypczyk, T Suchojad, D Wojtkowiak, B Zaforemski, L Zapala, A Zemla, P Radziszewski
Adjuvant diagnostic and therapeutic procedures are available to reduce the risk of recurrence or progression in patients with high-risk non-muscle-invasive bladder cancer (NMIBC). However, their indications and efficacy remain a matter of debate. The aim of this study was to analyze therapeutic decisions in patients with primary high-risk NMIBC and to analyze the adherence to clinical guidelines in this field.545 consecutive patients, aged a median of 70.3 years, diagnosed with primary high-risk NMIBC in thirteen urological institutions, were enrolled into this retrospective study...
2018: Neoplasma
https://www.readbyqxmd.com/read/29287519/isolated-red-patches-seen-during-endoscopic-surveillance-of-bladder-cancer-when-should-we-biopsy
#2
Nkwam Nkwam, Shaun Trecarten, Stefan Momcilovic, Alvaro E Bazo, Gurminder S Mann, Benedict Sherwood, Richard Parkinson
OBJECTIVE: To establish whether the regular biopsy of red patches seen during endoscopic surveillance for bladder cancer is worthwhile and determine a suitable time frame for repeat biopsy of prior histologically benign persistent red patches in patients on endoscopic surveillance for bladder cancer. PATIENTS AND METHODS: 4,805 flexible cystoscopy reports over a 12-month period were retrospectively reviewed at a UK tertiary teaching hospital and those undergoing cystoscopic surveillance for bladder cancer and found to have solitary red patches at flexible cystoscopy were included in the study...
December 29, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/29286018/miliary-pulmonary-infection-after-bcg-intravesical-instillation-a-rare-misdiagnosed-and-mistreated-complication
#3
Giorgio Calleris, Giancarlo Marra, Silvia Corcione, Marco Oderda, Chiara Cardellino, Sabrina Audagnotto, Bruno Frea, Francesco Giuseppe De Rosa, Paolo Gontero
Intravesical Bacillus Calmette-Guérin (BCG) immunotherapy decreases the progression risk of non-muscle-invasive bladder cancer, but potentially yields a broad spectrum of side effects. We report the case of a 73-year-old man affected by miliary pulmonary BCG infection, whose microbiological diagnosis was probably hindered by empiric fluoroquinolones, focusing on imaging and clinical work-up.
December 1, 2017: Le Infezioni in Medicina
https://www.readbyqxmd.com/read/29281857/outcomes-of-subsequent-non-muscle-invasive-bladder-cancer-treated-with-intravesical-bacillus-calmette-gu%C3%A3-rin-after-radical-nephroureterectomy-for-upper-urinary-tract-urothelial-carcinoma-a-propensity-matched-analysis-with-primary-bladder-cancer
#4
Makito Miyake, Yoshihiro Tatsumi, Hiroaki Matsumoto, Kazuhiro Nagao, Hideyasu Matsuyama, Teruo Inamoto, Haruhito Azuma, Hiroaki Yasumoto, Hiroaki Shiina, Kiyohide Fujimoto
OBJECTIVES: To describe the clinicopathologic characteristics and prognosis of subsequent non-muscle invasive bladder cancer (NMIBC) after radical nephroureterectomy for upper urinary tract urothelial carcinoma (UTUC), particularly its response to intravesical Bacillus Calmette-Guérin (BCG). PATIENTS AND METHODS: An observational study was conducted in 1463 patients with UTUC who had undergone radical nephroureterectomy and in 1555 patients with primary NMIBC. Of the 1463 UTUC patients, 256 (17%) subsequently developed NMIBC (UTUC-NMIBC) and were available for the analysis...
December 27, 2017: BJU International
https://www.readbyqxmd.com/read/29273406/re-radical-cystectomy-bladder-removal-against-intravesical-bcg-immunotherapy-for-high-risk-non-muscle-invasive-bladder-cancer-bravo-a-protocol-for-a-randomised-controlled-feasibility-study
#5
https://www.readbyqxmd.com/read/29212486/emerging-concepts-and-spectrum-of-renal-injury-following-intravesical-bcg-for-non-muscle-invasive-bladder-cancer
#6
Azharuddin Mohammed, Zubair Arastu
BACKGROUND: Intravesical Bacilli Calmette-Guerin (IVBCG) therapy for non-muscle invasive bladder cancer (NMIBC) has long been in use successfully. Albeit rarely, we still face with its safety concerns more than 25 years on since its approval by US Food and Drug Agency in 1990. Local and systemic infection following intravesical BCG is widely reported as compared to immune mediated local or systemic hypersensitivity reactions involving kidneys; acute kidney injury (AKI) and other renal manifestations are well reported but not of chronic kidney disease (CKD)...
December 6, 2017: BMC Urology
https://www.readbyqxmd.com/read/29209984/intravesical-thalidomide-boosts-bacillus-calmette-gu%C3%A3-rin-bcg-in-non-muscle-invasive-bladder-cancer-treatment
#7
Gabriela R Passos, Juliana A Camargo, Karen L Ferrari, Mário J A Saad, Amilcar C de Mattos, Leonardo O Reis
The aim of this study was to explore the efficacy of intravesical Thalidomide (immunomodulatory, anti-inflammatory and anti-angiogenic) added to BCG using an immune competent autochthonous orthotopic NMIBC animal model. Female Fischer 344 rats, 7 weeks of age, received every 2 weeks for four times, a dose of 1.5 mg/kg of N-methyl-N-nitrosourea (MNU) intravesically. The rats were randomized into four groups (n = 10 per group) to receive intravesical treatment once a week for 6 weeks as follows: control (0...
December 4, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29201501/alternative-therapies-in-patients-with-non-muscle-invasive-bladder-cancer
#8
REVIEW
Öner Şanlı, Yair Lotan
Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required...
December 2017: Turkish Journal of Urology
https://www.readbyqxmd.com/read/29174504/intravesical-immunomodulatory-imiquimod-enhances-bacillus-calmette-gu%C3%A3-rin-downregulation-of-nonmuscle-invasive-bladder-cancer
#9
Juliana A Camargo, Gabriela R Passos, Karen L Ferrari, Athanase Billis, Mário J A Saad, Leonardo O Reis
BACKGROUND: The Toll-like receptor (TLR)2/4 agonist bacillus Calmette-Guérin (BCG), although not failure proof, has been the most efficient immunomodulatory treatment of immunogenic nonmuscle-invasive bladder cancer (NMIBC) for > 40 years. We investigated the role of the immunomodulatory molecule TLR7 agonist imiquimod through the BCG key receptors TLR2/4 and the main downstream molecules of the mammalian target of rapamycin pathway in NMIBC treatment. MATERIALS AND METHODS: A total of 40 Fischer-344 rats, 7 weeks old, received 4 doses of 1...
November 7, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29164059/intravesical-gemcitabine-versus-intravesical-bacillus-calmette-gu%C3%A3-rin-for-the-treatment-of-non-muscle-invasive-bladder-cancer-an-evaluation-of-efficacy-and-toxicity
#10
Thiru Prasanna, Paul Craft, Gayathri Balasingam, Hodo Haxhimolla, Ganes Pranavan
Background: Intravesical Bacillus Calmette-Guérin (BCG) remains the standard adjuvant treatment for non-muscle invasive bladder cancer (NMIBC) following transurethral resection; however, BCG failure and related toxicities are common. Objectives: To compare the efficacy and toxicity of intravesical BCG and gemcitabine in the treatment of NMIBC. Methods: Retrospective data were collected in the region of Canberra, Australia from January 2010 to December 2015...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/29152556/bladder-sparing-therapy-for-bcg-failures-i-intravesical-immunotherapy
#11
Edward M Messing
No abstract text is available yet for this article.
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29152553/oncological-outcomes-of-sequential-intravesical-gemcitabine-and-docetaxel-in-patients-with-non-muscle-invasive-bladder-cancer
#12
Niv Milbar, Max Kates, Meera R Chappidi, Filippo Pederzoli, Takahiro Yoshida, Alexander Sankin, Phillip M Pierorazio, Mark P Schoenberg, Trinity J Bivalacqua
Background: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). Objective: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies...
October 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/29145329/new-onset-of-myasthenia-gravis-after-intravesical-bacillus-calmette-guerin-a-case-report-and-literature-review
#13
Tsubasa Takizawa, Marenori Kojima, Shigeaki Suzuki, Takashi Osada, Satoshi Kitagawa, Jin Nakahara, Shinichi Takahashi, Norihiro Suzuki
RATIONALE: Recently, drug-related myasthenia gravis (MG) has received attention, because the number of reported cases involving MG associated with immune checkpoint inhibitors, a new immunotherapy, is increasing. We present a case involving the new onset of MG, in which the symptoms started shortly after intravesical Bacillus Calmette-Guerin (BCG) for bladder cancer. PATIENT CONCERNS: A 69-year-old male with bladder cancer developed ptosis and diplopia 4 days after the completion of a treatment regimen with intravesical BCG weekly for 6 weeks...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29118530/prognostic-impact-of-bacillus-calmette-gu%C3%A3-rin-interruption-at-the-time-of-induction-and-consolidation
#14
M Mofarej Alhogbani, J Aude Picard, M Hakim Fassi-Fehri, J Lionel Badet, C Marc Colombel
Context: Intravesical Bacillus Calmette-Guérin (BCG) is a cause of bladder and systemic toxicity that is difficult to prevent and is responsible for treatment drop out in bladder cancer patients. More recently, BCG shortage has become the main cause of incomplete treatment. Aims: The aim of this study was to examine the impact on long-term prognosis of bladder cancer patients following discontinuation of BCG instillations. Settings and Design: In this retrospective study, data were examined from 333 consecutive nonmuscle invasive bladder cancer patients treated from 2005 to 2015 by transurethral resection (TUR) and had undergone adjuvant BCG therapy after TUR...
October 2017: Urology Annals
https://www.readbyqxmd.com/read/29103257/-fever-hepatic-dysfunction-and-interstitial-pneumonia-caused-by-intravesical-bacillus-calmette-guerin-bcg-instillation-after-urethral-bougie-a-case-report
#15
Satoshi Nitta, Shotaro Sakka, Tsuyoshi Endo, Manabu Komine, Masakazu Tsutsumi, Hiroyuki Nishiyama
A 60-year-old man had a past history of urothelial carcinoma of the left renal pelvis treated with laparoscopic left total nephroureterectomy in October 2004. He underwent transurethral resection of the bladder tumor (TUR-Bt) twice for recurrence of urothelial carcinoma in the bladder in April 2014 and February 2015, and subsequently received intravesical Bacillus Calmette-Guerin (BCG) instillation at weekly intervalsfor prevention of recurrence. In November 2016, a year and a half after BCG induction, he received BCG therapy after urethral bougie to dilate the urethral stricture...
October 2017: Hinyokika Kiyo. Acta Urologica Japonica
https://www.readbyqxmd.com/read/29101762/availability-and-patterns-of-intravesical-bcg-instillations
#16
S Awomir Poletajew, Aleksandra Majek, Piotr Magusiak, Katarzyna Ledzikowska, Bartosz Dybowski, Piotr Radziszewski
PURPOSE: Intravesical BCG instillations improve recurrence free survival in patients with non-muscle-invasive bladder cancer (NMIBC). METHODS: This is a national survey study, covering 223 urological centres, aimed at reliable identification of BCG availability and implemented treatment patterns. RESULTS: Response rate was 93.7%. BCG was used in 56.5% of urological departments. Another 22.7% referred patients to other hospitals for instillations, while 20...
November 4, 2017: Urology Journal
https://www.readbyqxmd.com/read/29093394/mycobacterium-bovis-induced-aneurysm-after-intravesical-bacillus-calmette-gu%C3%A3-rin-therapy-a-case-study-and-literature-review
#17
Yoshitsugu Higashi, Shigeki Nakamura, Kento Kidani, Kaoru Matumoto, Koyomi Kawago, Junko Isobe, Junichi Kanatani, Yukio Kawagishi, Ippei Sakamaki, Yoshihiro Yamamoto
Mycobacterium bovis infection after intravesical Bacillus Calmette-Guérin (BCG) therapy is rare. A 65-year-old Japanese man with history of bladder cancer and intravesical BCG therapy, presented with low-grade fever. An aneurysm with perianeurysmal fluid was suspected and endovascular aortic repair was performed. After 160 days, he developed blood-streaked sputum and computed tomography images revealed that the perianeurysmal fluid area was increasing in size. A multiplex polymerase chain reaction using sputum identified M...
November 1, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29081034/primary-high-grade-non-muscle-invasive-bladder-cancer-high-nf%C3%AE%C2%BAb-expression-in-tumor-specimens-distinguishes-patients-who-are-at-risk-for-disease-progression
#18
Lampros Mitrakas, Stavros Gravas, Christos Papandreou, Georgios Koukoulis, Foteini Karasavvidou, Georgios Dimakopoulos, Karl Weingärtner, Anastasios Karatzas, Ioannis Zachos, Vasilios Tzortzis
To investigate the potential prognostic role of NFκB expression in primary high-grade non-muscle-invasive bladder cancer. Patients with primary high-grade non-muscle-invasive bladder cancer who received induction and maintenance BCG therapy were retrospectively included. Recurrence and progression were histologically proven. Intensity and extent of immunochemistry were assessed. The final evaluation of the NFκB staining was done by combining intensity and extent as ΄΄product΄΄ and expressing it as ΄΄low NFκΒ expression΄΄ or ΄΄high NFκB expression΄΄...
October 28, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29074812/pleural-effusion-as-a-late-complication-of-intravesical-bcg-treatment
#19
Ailish Nimmo, Amy Gray, Aarti Patel, Joseph MacKenzie, Ian Fairbairn
No abstract text is available yet for this article.
October 26, 2017: Thorax
https://www.readbyqxmd.com/read/29059771/re-anti-inflammatory-use-may-not-negatively-impact-oncologic-outcomes-following-intravesical-bcg-for-high-grade-non-muscle-invasive-bladder-cancer
#20
keyword
keyword
7101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"